文献速递临床试验与 GCP医学教育与科研方法

临床研究报告——系统综述与主题综合:第2部分——研究药物干预的获益、损害及获益-损害平衡

Clinical Study Reports-a systematic review with thematic synthesis: Part 2. Studying benefits, harms, and the benefit to harm balance of pharmacological interventions.
PubMed 文献 · Trials · 2025-05-01

本系统综述检索多种数据库纳入含「临床研究报告」的出版物,主题综合讨论临床研究报告用于评估药物干预的个体获益与损害及获益-损害平衡。结论指出,与已发表试验报告相比,临床研究报告显示的获益较不显著、损害信息更多,使获益-损害平衡估计通常更不利;监管机构和制造商应继续公开完整临床研究报告,尚未公开的机构应予公开,并应将临床研究报告引入手术、治疗器械等非药物干预试验的评估。

要点

  • 与已发表试验报告相比,临床研究报告显示的药物干预获益较不显著。
  • 临床研究报告可提供更多药物干预所致损害的信息。
  • 上述两种效应改变药物干预获益-损害平衡的估计,通常使其较原本认为的更不利。

核心结论

  • 与已发表试验报告中的数据相比,临床研究报告中的药物干预获益较不显著,且可发现更多损害信息,二者通常使获益-损害平衡估计较原本认为的更不利。
  • 为更准确评估干预的获益-损害平衡,监管机构和制造商应继续公开完整而非节略或概要版的临床研究报告,尚未公开的机构应予公开。
  • 应将临床研究报告引入手术、治疗器械及其他非药物干预临床试验的评估。

研究设计与样本

  • 系统综述,检索Clarivate Web of Science、EMBASE与Ovid Medline、Google Scholar和PubMed中含「clinical study report/s」的出版物,未设限制。
  • 本文为综述第2部分,采用主题综合讨论临床研究报告的用途,聚焦药物干预的个体获益与损害及获益-损害平衡。
  • 同时讨论对干预的依从性、临床试验方案的发表前公开以及临床研究报告的撰写方式,这些因素均可影响获益-损害平衡的估计。

主要发现

  • 与已发表试验报告相比,临床研究报告显示的药物干预获益较不显著。
  • 与已发表试验报告相比,临床研究报告可提供更多药物干预所致损害的信息。
  • 上述两种效应均改变药物干预获益-损害平衡的估计,通常使其较原本认为的更不利。

临床怎么用

  • 作者认为,为更准确评估干预的获益-损害平衡,监管机构和制造商应继续公开完整而非节略或概要版的临床研究报告。
  • 作者认为,尚未公开临床研究报告的机构应予公开。
  • 作者认为,应将临床研究报告引入手术、治疗器械及其他非药物干预临床试验的评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We define clinical study reports (CSRs) as standardized full reports of the protocols, results, and other pertinent details of clinical studies that are typically submitted by pharmaceutical companies to regulatory authorities when they apply for marketing authorization. METHODS: In this systematic review we searched various databases (Clarivate Web of Science, EMBASE and Ovid Medline, Google Scholar, and PubMed) for publications containing the term "clinical study report/s", without restrictions. THEMATIC SYNTHESIS: In the first part of this review we discussed the history of CSRs, their contents and structure, definitions, and relevant terminology. In this second part we discuss the uses of CSRs, concentrating on the individual benefits and harms of pharmacological interventions, and thus the benefit to harm balance. We also discuss adherence to interventions, prepublication of protocols of clinical trials, and how CSRs are written, factors that can all affect estimation of the benefit-harm balance. CONCLUSIONS: When clinical trial data from CSRs are compared with the data in published trial reports, the apparent benefits of pharmacological interventions are less impressive, and more information emerges about harms they can cause. Both of these effects change how the benefit-harm balance of a pharmacological intervention is estimated, generally making it less favourable than was otherwise thought. For more accurate assessment of the benefit-harm balance of an intervention, full, not abbreviated or synoptic, clinical study reports should continue to be made publicly available by regulatory authorities and manufacturers. Authorities that do not currently make them available should do so. CSRs should be introduced for assessment of surgical operations, therapeutic devices, and other non-pharmacological interventions in clinical trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Aronson JK, Onakpoya IJ. Clinical Study Reports-a systematic review with thematic synthesis: Part 2. Studying benefits, harms, and the benefit to harm balance of pharmacological interventions. Trials. 2025. PMID: 40312342. doi:10.1186/s13063-024-08671-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。